The Swiss Pharmaceuticals Roche and Mysugr, a company care for people with diabetes, announced on June 30 an agreement by which Roche acquired all the actions of MySugr GmbH.
By virtue of this agreement, MySugong will become an integral part of the new digital health services -centered diabetes platform that Roche will launch, while the Swiss pharmacist expands its leadership position in the area ofDiabetes management.
Roland Diggelmann, general director of Roche Diagnostics, declared that “we are excited about this agreement, since we will be able to offer patients easily accessible solutions within an open platform to better respond to the unsatisfied needs of people with diabetes.Our goal is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life. ”
"After associating with MySugr since 2014, we see an excellent cultural adjustment, since both companies are committed to bringing diabetes management to a higher level and making a difference in the management of diabetes," added Diggelmann.
Frank Westermann, CEO and co -founder of MySugr, commented that "we started MySugg to solve our daily problems and simplify diabetes therapy through smartphones."
"The MySugong team has covered a vacuum that existed so far for more than one million users, and with Roche's experience in diabetes and the global network, Mysugg will become an indispensable partner for a life without complications," Westermann settled.
As a focal point for the Integrated Roche Diabetes Management Strategy, Mysugr is expected to remain an independent legal entity with an open platform for all devices and services for diabetes.Users will continue to have the ability to automatically load blood glucose data from their preferred device in the Mysugr registration application, as well as the exchange of data provided with health professionals and caregivers.